In a preclinical study using an OBP-301 variant for mice (OBP-502), we showed that OBP-502 local treatment strongly induced immunogenic cell death (ICD), leading to recruitment of CD8 + T cells into tumors and provided strong anti-tumor effects [9]. This evidence concerns the gene CD8A and neoplasm.